Department of Clinical, Azidus Laboratories Ltd, Chennai, Tamil Nadu, India
Research Article
An Open Label, Balanced, Randomized, Two Treatments, Two Sequences, Two Periods, Single Dose, Cross Over, Oral Bioequivalence Study of Vildagliptin 50 Mg Tablets of Abbott Laboratories De Colombia vs. Jalra (Vildagliptin) 50 Mg Tablets of Novartis Pharma Stein Ag, in Healthy, Adult, Human Subjects Under Fasting Condition
Author(s): O. Arjun Arumugam*, Geetha Lakshmi G, Srinivas G, Nageswara Rao T, Hurtado-Colorado K, Perez-Perez M, Gavino-Gutierrez AM, Lara C, Higuera MJ and Penaloza I
Vildagliptin is dipeptidyl peptidase 4 (DPP-4) inhibitors, that inhibits rapid and complete inhibition of DPP-4 activity, resulting in increased fasting and
postprandial endogenous levels of the incretin hormones GLP-1 (glucagon-like peptide 1) and GIP (glucose-dependent insulinotropic polypeptide)
in the treatment of type 2 diabetes mellitus in adults. The purpose of this study was to evaluate the bioequivalence between Vildagliptin 50 mg
Tablets of Abbott Laboratories de Colombia vs. JALRA (Vildagliptin) 50 mg Tablets of Novartis Pharma Stein AG, in healthy subjects under fasting
condition. An open label, balanced, randomized, two treatments, two sequences, two periods, single dose, cross over study with washout period
of 03 days under fasting condition was carried out in 42 male subjects in the age group of 19 to 43 years who met the study eligibility criteria, .. Read More»
DOI:
10.37421/1948-593X.2023.15.366
Journal of Bioanalysis & Biomedicine received 2821 citations as per Google Scholar report
